KNOWLEDGE CENTER

Clinical Studies

The use of advanced spectral imaging to reveal nanoparticle identity in biological samples

March 30, 2022

ASI's Hyperspectral imaging and analysis system, SpectraView, integrated with artificial intelligence-driven analysis allows differentiation between the core and the shell of Nanoparticles (NPs) for the first time. The advances of spectral imaging resolution and analysis also allow to detect the dynamics of NP distribution, tracking and identifying NPs and their subcellular localizations in single living cells.

Read More

Philadelphia-like acute lymphoblastic leukemia: Characterization in a pediatric cohort in a referral center in Colombia

December 14, 2021

ASI’s digital imaging and analysis solutions utilized for evaluation of the frequency and clinical and biological characteristics of Philadelphia-like acute lymphoblastic leukemia.

Read More

Anti-neoplastic and demethylating activity of a newly synthetized flavanone-derived compound in Renal Cell Carcinoma cell lines

July 28, 2021

Renal Cell Carcinoma (RCC) is on the top 10 of the most incident cancers worldwide, being a third of patients diagnosed with advanced disease, for which no curative therapies are currently available. Thus, new effective therapeutic strategies are urgently needed.

Read More

Targeting novel LSD1-dependent ACE2 demethylation domains inhibits SARS-CoV-2 replication

June 1, 2021

Treatment options for COVID-19 remain limited, especially during the early or asymptomatic phase. Here, we report a novel SARS-CoV-2 viral replication mechanism mediated by interactions between ACE2 and the epigenetic eraser enzyme LSD1, and its interplay with the nuclear shuttling importin pathway. Recent studies have shown a critical role for the importin pathway in SARS-CoV-2 infection, and many RNA viruses hijack this axis to re-direct host cell transcription.

Read More

Label‑free spectral imaging to study drug distribution and metabolism in single living cells

February 3, 2021

During drug development, evaluation of drug and its metabolite is an essential process to understand drug activity, stability, toxicity and distribution. Liquid chromatography (LC) coupled with mass spectrometry (MS) has become the standard analytical tool for screening and identifying drug metabolites. Unlike LC/MS approach requiring liquifying the biological samples, we showed that spectral imaging (or spectral microscopy) could provide high‑resolution images of doxorubicin (dox) and its metabolite doxorubicinol (dox’ol) in single living cells. Using this new method, we performed measurements without destroying the biological samples

Read More

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7